Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 10376 - 10400 of 12439 in total
Opiranserin is under investigation in clinical trial NCT03997838 (Evaluate the Efficacy and Safety of VVZ-149 Injections for the Treatment of Post-operative Pain Following Abdominoplasty).
Investigational
Matched Description: … VVZ-149 Injections for the Treatment of Post-operative Pain Following Abdominoplasty). ... Opiranserin is under investigation in clinical trial NCT03997838 (Evaluate the Efficacy and Safety of
Rilzabrutinib is an oral, reversible covalent inhibitor of Bruton's tyrosine kinase being investigated for the treatment of immune disorders, such as immune thrombocytopenic purpura.[A259073, A259078]
Investigational
Matched Description: … for the treatment of immune disorders, such as immune thrombocytopenic purpura. ... Rilzabrutinib is an oral, reversible covalent inhibitor of Bruton's tyrosine kinase being investigated …
CRx-139 is an oral synergistic combination drug candidates with novel mechanisms of action targeting multiple biological pathways simultaneously. It is a dissociated steroid designed to enhance the immuno-modulatory activity of a low-dose glucocorticoid steroid without a comparable increase in steroid-related side effects. The synergistic combination containing low doses of the...
Investigational
Matched Description: … CRx-139 is an oral synergistic combination drug candidates with novel mechanisms of action targeting ... This novel synergistic combination is developed for the treatment of immuno-inflammatory diseases. ... It is a dissociated steroid designed to enhance the immuno-modulatory activity of a low-dose glucocorticoid …
Adherex's biotechnology compound, ADH-1, targets N-cadherin, a protein present on certain tumor cells and established tumor blood vessels. ADH-1 is currently in clinical development in a combination program with a range of chemotherapeutic agents to investigate the synergistic effects noted in our preclinical models. At the end of 2006, the...
Investigational
Matched Description: … Phase II trials of ADH-1. ... ADH-1 may have utility in a wide variety of cancers as N-cadherin is overexpressed in a variety of tumors ... causing angiolysis (disruption of blood vessels) and tumor damage. …
Aminocandin is a new representative of the echinocandins that could potentially affect the cellular morphology and metabolic status of Candida albicans cells within biofilms.
Investigational
Matched Description: … and metabolic status of Candida albicans cells within biofilms. ... Aminocandin is a new representative of the echinocandins that could potentially affect the cellular morphology …
Veltuzumab is a monoclonal antibody which, as of October 2009, is undergoing Phase I/II clinical trials for the treatment of non-Hodgkin's lymphoma.
Investigational
Matched Description: … for the treatment of non-Hodgkin's lymphoma. ... Veltuzumab is a monoclonal antibody which, as of October 2009, is undergoing Phase I/II clinical trials …
PF-04937319 is under investigation in clinical trial NCT01513928 (A Study To Compare The Pharmacokinetics Of Different Formulations Of PF-04937319 In Healthy Subjects).
Investigational
Matched Description: … Different Formulations Of PF-04937319 In Healthy Subjects). ... 04937319 is under investigation in clinical trial NCT01513928 (A Study To Compare The Pharmacokinetics Of
PF-06650833 is under investigation in clinical trial NCT02609139 (Study to Evaluate Pharmacokinetics of A Modified Release Formulation of PF-06650833 in Healthy Subjects).
Investigational
Matched Description: … A Modified Release Formulation of PF-06650833 in Healthy Subjects). ... PF-06650833 is under investigation in clinical trial NCT02609139 (Study to Evaluate Pharmacokinetics of
Duvortuxizumab is under investigation in clinical trial NCT02743546 (Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma).
Investigational
Matched Description: … , Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma). ... Duvortuxizumab is under investigation in clinical trial NCT02743546 (Study of the Safety, Pharmacokinetics …
Dexisometheptene mucate is under investigation in clinical trial NCT02423408 (Safety and Efficacy Study of TNX-201 Capsules for Treatment of Single Tension-type Headache).
Investigational
Matched Description: … TNX-201 Capsules for Treatment of Single Tension-type Headache). ... Dexisometheptene mucate is under investigation in clinical trial NCT02423408 (Safety and Efficacy Study of
Epafipase is under investigation in clinical trial NCT00037687 (Safety and Efficacy of Recombinant Human Platelet-activating Factor Acetylhydrolase for the Treatment of Severe Sepsis).
Investigational
Matched Description: … Platelet-activating Factor Acetylhydrolase for the Treatment of Severe Sepsis). ... Epafipase is under investigation in clinical trial NCT00037687 (Safety and Efficacy of Recombinant Human …
L-3972-T is one of the components of the human papilloma virus (HPV) type 16 E6/E7 synthetic long peptide (SLP) vaccine ISA101b.
Investigational
Matched Description: … L-3972-T is one of the components of the human papilloma virus (HPV) type 16 E6/E7 synthetic long peptide …
Lumicitabine is under investigation in clinical trial NCT03010059 (A Study to Assess the Relative Bioavailability of JNJ64041575 Administered as 2 Different New Concept Formulations (Oral Suspension and Tablet) Compared to Their Respective Current Formulations, and to Assess the Effect of Food on the Pharmacokinetics of the 2 New Concept Formulations).
Investigational
Matched Description: … Food on the Pharmacokinetics of the 2 New Concept Formulations). ... is under investigation in clinical trial NCT03010059 (A Study to Assess the Relative Bioavailability of ... Suspension and Tablet) Compared to Their Respective Current Formulations, and to Assess the Effect of
Peldesine is a potent inhibitor of human CCRF-CEM T-cell proliferation. It has undergone phase I trials for the treatment of Human Immunodeficiency Virus (HIV) infections.
Investigational
Matched Description: … Peldesine is a potent inhibitor of human CCRF-CEM T-cell proliferation. ... It has undergone phase I trials for the treatment of Human Immunodeficiency Virus (HIV) infections. …
SL017 formulated as a topical gel, has been combined with a widely available light source for permanent removal of unwanted hair and for treatment of actinic keratosis
Investigational
Matched Description: … unwanted hair and for treatment of actinic keratosis ... formulated as a topical gel, has been combined with a widely available light source for permanent removal of
Levilimab is under investigation in clinical trial NCT04227366 (Study of the Efficacy and Safety of BCD-089 in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis).
Investigational
Matched Description: … Levilimab is under investigation in clinical trial NCT04227366 (Study of the Efficacy and Safety of BCD …
VaxSyn HIV-1 is a recombinant form of the HIV envelope protein gp 160 developed by MicroGeneSys and the National Institute of Allergy and Infectious Diseases (NIAID).
Investigational
Matched Description: … National Institute of Allergy and Infectious Diseases (NIAID). ... VaxSyn HIV-1 is a recombinant form of the HIV envelope protein gp 160 developed by MicroGeneSys and the …
CRx-401 is a novel insulin sensitizer designed to provide anti-diabetic activity without promoting weight gain. It consists of a low dose of the analgesic diflunisal in conjunction with a modified-release therapeutic dose of bezafibrate, an anti-cholesterol agent. In third-party clinical studies, the dose of bezafibrate contained in CRx-401 has been...
Investigational
Matched Description: … It consists of a low dose of the analgesic diflunisal in conjunction with a modified-release therapeutic ... dose of bezafibrate, an anti-cholesterol agent. ... In third-party clinical studies, the dose of bezafibrate contained in CRx-401 has been observed to have …
Amcipatricin has been used in trials studying the treatment of Cryptococcosis or Aspergillosis Infections. Amcipatricin (as amcipatricin diascorbate; SPK-843) is a water-soluble partricin derivative patented by SPA Societa Prodotti Antibiotici S.p.A. and developed by Aparts and Kaken for the potential treatment of systemic fungal infections. In preclinical models, SPK-843 shows...
Investigational
Matched Description: … SPK-843 doses of higher than 1.0 mg/kg of body weight exhibit no renal toxicities and a tendency toward ... Amcipatricin has been used in trials studying the treatment of Cryptococcosis or Aspergillosis Infections ... SPA Societa Prodotti Antibiotici S.p.A. and developed by Aparts and Kaken for the potential treatment of
CNS 5161 is a blocker of the NMDA ion channel and has completed Phase IIa proof of concept clinical trials as a novel compound for the treatment of neuropathic pain.
Investigational
Matched Description: … CNS 5161 is a blocker of the NMDA ion channel and has completed Phase IIa proof of concept clinical trials ... as a novel compound for the treatment of neuropathic pain. …
A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.
Experimental
Matched Description: … Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts. ... It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. …
Glymera is under investigation in clinical trial NCT01658501 (Phase 2b Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM).
Investigational
Matched Description: … Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM). ... Double-blind, Placebo- and Active-controlled, Parallel-group Study to Assess the PD Response and Safety of
An ester of beclomethasone.
Experimental
Matched Description: … An ester of beclomethasone. …
rhMBL is a protein therapeutic being developed by Enzon for the prevention and treatment of severe infections in individuals with low levels of Mannose-Binding Lectin (MBL). Over 10 percent of the general population is estimated to be MBL-deficient. Natural MBL is a 400-700kDa oligomer made of 3 identical 32kDa peptide...
Investigational
Matched Description: … in individuals with low levels of Mannose-Binding Lectin (MBL). ... Over 10 percent of the general population is estimated to be MBL-deficient. ... Natural MBL is a 400-700kDa oligomer made of 3 identical 32kDa peptide chains. …
Mitoquinone is based on a novel technology, targeted lipophilic cations, that transport and concentrate antioxidants into the mitochondria -- organelles inside cells that provide energy for life processes -- where they accumulate up to a thousand fold. In 2004, a genomic study of hereditary early-onset Parkinson's disease demonstrated a direct...
Investigational
Matched Description: … the sporadic form of Parkinson's disease. ... link between mitochondrial dysfunction and the pathogenesis of Parkinson's disease. ... In 2004, a genomic study of hereditary early-onset Parkinson's disease demonstrated a direct molecular …
Displaying drugs 10376 - 10400 of 12439 in total